Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cream aims to keep acne away after strong medication

NCT ID NCT07341659

Disease control Sponsor: Pierre Fabre Dermo Cosmetique Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a cosmetic cream (RV3278B-OS0386) to see if it can stop acne from returning after a full course of oral isotretinoin. About 102 adults with clear or almost clear skin after isotretinoin will use the cream or a control product twice daily for 12 months. The main goal is to measure how many people have an acne relapse during that time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cosmetic cream (RV3278B-OS0386)
What this could lead to
If it works, this cream could help keep acne away after a course of isotretinoin, reducing the chance of relapse.
What could go wrong
This is a small, early-stage cosmetic study, not a drug trial. The cream may not prevent relapse better than a control product, and results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

102 people

The number who actually took part.

Started

Feb 2025

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or Female aged between 15 and 35 years included * Subject affiliated to a social security system or health insurance, or is a beneficiary if applicable * Subject who recently completed his/her first course of oral isotretinoin treatment * Subject with clear or almost clear facial acne Non Inclusion criteria: * Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements * Facial skin disease other than acne, skin abnormalities, or dermatological condition on the face liable to interfere with the study assessments * Severe or complicated cases of acne (ex: acne conglobate) according to investigator's assessment * Any acute, chronic or progressive disease or medical history liable to interfere with the study data or considered by the Investigator hazardous for the subject or incompatible with the study requirements * Any surgery, chemical (e.g.: skin peel) or physical treatment on the face done within 12 months before the inclusion or planned during the study * Topical or systemic product or treatment established or modified during the previous weeks or planned to be established or modified during the study, liable to interfere with the evaluation of the efficacy or cutaneous tolerance of the investigational product according to the investigator's assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acne are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acne Acne Vulgaris

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acne

Contacts and locations

Locations

  • Centre de santé Sabouraud

    Paris, 75010, France

  • Dr. E.Karamon Private Practice

    Malbork, Poland, 82200, Poland

  • Dr. I.Karamon Private Practice

    Gdansk, 80280, Poland

  • Humanitas Research Hospital - Unita dermatologica

    Milan, 20089, Italy

  • Istituto Dermopatico dell'Immacolata in Roma

    Roma, 00167, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.